Related Experiment Video
Updated: Jun 10, 2026
06:55
Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
What do international pharmacoeconomic guidelines say about economic data transferability?
Marco Barbieri1, Michael Drummond, Frans Rutten
1i3 Innovus, Uxbridge, Middlesex, UK.
Summary
National pharmacoeconomic guidelines show diverse recommendations on data transferability. Standardization is needed, especially for resource use and utilities, to improve pharmaceutical economic evaluations.
Area of Science:
- Health Economics
- Pharmaceutical Policy
- Evidence Synthesis
Background:
- National pharmacoeconomic guidelines are increasingly used for pharmaceutical economic evaluations.
- Assessing the transferability of clinical and economic data across different settings is crucial for robust evaluations.
- Existing guidelines present varied approaches to data transferability, impacting consistency.
Purpose of the Study:
- To evaluate national pharmacoeconomic guidelines regarding the transferability of clinical and economic data.
- To review methodologies proposed in guidelines for addressing data transferability challenges.
- To identify differences and commonalities in transferability recommendations across countries.
Main Methods:
- Systematic review of national pharmacoeconomic guidelines.
- Identification of guidelines through the ISPOR website and other sources.
- Analysis of recommendations on the transferability of specific data types (e.g., baseline risk, unit costs, treatment effect, resource use, utilities).
Main Results:
- Baseline risk and unit costs are consistently viewed as having low transferability.
- Treatment effect is generally considered highly transferable.
- Resource use (63%) and utilities (45%) show variable transferability, often considered low.
Conclusions:
- Pharmacoeconomic guidelines exhibit diverse recommendations on data transferability.
- There is a need for greater standardization in addressing transferability issues in pharmaceutical evaluations.
- More frequent updates of existing guidelines are recommended to reflect evolving practices.
Related Concept Videos
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.